Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab, Disitamab Vedotin, and Carboplatin for Resectable HER2-Mutant NSCLC
NCT06734182Phase 2Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs), Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, disitamab vedotin in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Started Jun 2024; status: recruiting.
02
Drugs
envafolimabdisitamab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06734182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734182.